Compare VFS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | BBIO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Vietnam | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 14.7B |
| IPO Year | N/A | 2019 |
| Metric | VFS | BBIO |
|---|---|---|
| Price | $3.33 | $77.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 20 |
| Target Price | $5.83 | ★ $77.55 |
| AVG Volume (30 Days) | 374.5K | ★ 1.7M |
| Earning Date | 11-21-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,554,394,588.00 | $353,780,000.00 |
| Revenue This Year | N/A | $127.64 |
| Revenue Next Year | $43.19 | $78.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 81.20 | 62.46 |
| 52 Week Low | $2.56 | $27.32 |
| 52 Week High | $4.65 | $78.44 |
| Indicator | VFS | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 64.82 |
| Support Level | $3.30 | $74.47 |
| Resistance Level | $3.51 | $77.48 |
| Average True Range (ATR) | 0.11 | 2.04 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 21.17 | 73.34 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.